Plain-English translation of NCT06790706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immunotherapy drugs called Domvanalimab and Zimberelimab in patients with six types of rare advanced cancers that have not responded to at least one prior treatment. These drugs work by helping your immune system recognize and fight cancer cells. The study is being run across five separate smaller trials, each focusing on a different rare cancer type.
Most rare cancers have been left behind in cancer treatment progress because they're too uncommon for large-scale drug testing. When standard treatments stop working, patients with rare cancers often have few or no good options left. This trial exists to test whether this new immunotherapy medication might offer hope to patients whose cancers have become resistant to older treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic regularly to receive the new medication (either as an infusion or injection, depending on your cancer type) and undergo blood tests and imaging scans to monitor your response. Some patients may also receive standard chemotherapy alongside the immunotherapy. Throughout the study, your doctors will track how you feel, measure your tumor size or markers, and check for side effects. The duration and exact schedule will depend on how your cancer responds and which of the six cancer subtypes you have.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.